 Receptor, Fibroblast Growth Factor, Type 1
"Receptor, Fibroblast Growth Factor, Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 contains three extracellular IMMUNOGLOBULIN C2-SET DOMAINS and is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM.
| Descriptor ID |
D051496
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.177 D12.776.543.750.630.440 D12.776.543.750.750.400.370.500
|
| Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 1- Receptor, Fibroblast Growth Factor, Type 1
- FGFR1 Protein
- Fibroblast Growth Factor Receptor 1
- fms-Like Tyrosine Kinase-2
- fms Like Tyrosine Kinase 2
- CD331 Antigen
- Antigen, CD331
- FGFR1 Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 1".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 1 [D08.811.913.696.620.682.725.400.177]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.630.440]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.750.400.370.500]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 1".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2005 | 2 | 0 | 2 | | 2006 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 3 | 1 | 4 | | 2015 | 4 | 1 | 5 | | 2017 | 1 | 2 | 3 | | 2018 | 3 | 0 | 3 | | 2019 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in Profiles.
-
L?tsch D, Kirchhofer D, Englinger B, Jiang L, Okonechnikov K, Senfter D, Laemmerer A, Gabler L, Pirker C, Donson AM, Bannauer P, Korbel P, Jaunecker CN, H?bner JM, Mayr L, Madlener S, Schmook MT, Ricken G, Maa? K, Grusch M, Holzmann K, Grasl-Kraupp B, Spiegl-Kreinecker S, Hsu J, Dorfer C, R?ssler K, Azizi AA, Foreman NK, Peyrl A, Haberler C, Czech T, Slavc I, Filbin MG, Pajtler KW, Kool M, Berger W, Gojo J. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021 08; 142(2):339-360.
-
Dela Cruz C, Horton CA, Sanders KN, Andersen ND, Tsai PS. Conditional Fgfr1 Deletion in GnRH Neurons Leads to Minor Disruptions in the Reproductive Axis of Male and Female Mice. Front Endocrinol (Lausanne). 2020; 11:588459.
-
Kim KB, Kim Y, Rivard CJ, Kim DW, Park KS. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer. Cancer Res. 2020 11 15; 80(22):5051-5062.
-
Hinz TK, Heasley LE. Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Semin Cancer Biol. 2020 04; 61:11-22.
-
Wilberger AC, McMahon B, Ewalt MD. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. Leuk Lymphoma. 2019 04; 60(4):1095-1097.
-
Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clin Lung Cancer. 2019 01; 20(1):e39-e51.
-
Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).
-
Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Jiang T, Zhou C, Heasley LE, Hirsch FR. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer. 2018 09; 19(5):450-456.
-
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, G?mez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017 Aug 09; 9(402).
-
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6138-6150.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|